

# Gerard Rosse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8135360/publications.pdf>

Version: 2024-02-01

30  
papers

60  
citations

1937685

4  
h-index

1720034

7  
g-index

30  
all docs

30  
docs citations

30  
times ranked

146  
citing authors

#	ARTICLE	IF	CITATIONS
1	Triazolo[4,5-d]pyrimidine Derivatives as Inhibitors of GCN2. ACS Medicinal Chemistry Letters, 2014, 5, 282-283.	2.8	22
2	Tricyclic Pyrimidines As Inhibitors of DYRK1A/DYRK1B As Potential Treatment for Downâ€™s Syndrome or Alzheimerâ€™s Disease. ACS Medicinal Chemistry Letters, 2013, 4, 502-503.	2.8	7
3	Quinoline Derivatives as 5-HT <sub>6</sub> Receptor PET Ligands. ACS Medicinal Chemistry Letters, 2014, 5, 275-276.	2.8	7
4	Pyridopyrimidines as Inhibitors of Hepatitis C Virus. ACS Medicinal Chemistry Letters, 2014, 5, 226-227.	2.8	4
5	Thiazolocarboxamide Analogues as NAMPT Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 277-277.	2.8	4
6	Imidazopyrazine Derivatives As Inhibitors of mTOR. ACS Medicinal Chemistry Letters, 2013, 4, 498-499.	2.8	3
7	Phenyl Carboxamide Analogues as Spleen Tyrosine Kinase (Syk) Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 278-279.	2.8	2
8	Novel Cycloalkenepyrzoles as Inhibitors of Bub1 Kinase. ACS Medicinal Chemistry Letters, 2014, 5, 280-281.	2.8	2
9	Aminotriazole and Aminotetrazole Inhibitors of LSD1 as Epigenetic Modulators. ACS Medicinal Chemistry Letters, 2016, 7, 132-133.	2.8	2
10	Diphenylpropane Derivatives as Agonist of PPAR Nuclear Receptors. ACS Medicinal Chemistry Letters, 2013, 4, 1135-1136.	2.8	1
11	HDAC Inhibitors as Targeted Treatment of Frontotemporal Lobar Degeneration. ACS Medicinal Chemistry Letters, 2013, 4, 7-7.	2.8	1
12	Pyrrolopyrimidine Analogues as MKNK Inhibitors. ACS Medicinal Chemistry Letters, 2015, 6, 9-10.	2.8	1
13	Diazaspiroonane Inhibitors of O-GlcNAc Hydrolase for the Treatment of Central Nervous System Diseases. ACS Medicinal Chemistry Letters, 2019, 10, 147-147.	2.8	1
14	Novel Methyl-aza-quinazolines as Inhibitors of the RAS-SOS Interaction. ACS Medicinal Chemistry Letters, 2020, 11, 2-3.	2.8	1
15	Substituted Imidazole Carboxamides as Novel Antibacterial Agents. ACS Medicinal Chemistry Letters, 2022, 13, 152-153.	2.8	1
16	A Series of Pyrazole Analogs Binding to KRASG12C as Potential Cancer Treatment. ACS Medicinal Chemistry Letters, 2022, 13, 11-12.	2.8	1
17	Imaging Probes of Tau Pathology. ACS Medicinal Chemistry Letters, 2013, 4, 817-818.	2.8	0
18	Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype. ACS Medicinal Chemistry Letters, 2013, 4, 500-501.	2.8	0

#	ARTICLE	IF	CITATIONS
19	Trisubstituted Imidazoles as Positive Modulators of Metabotropic Glutamate Receptor Subtype 5. ACS Medicinal Chemistry Letters, 2013, 4, 819-821.	2.8	0
20	Anabaseine Analogues as Modulators of Nicotinic Acetylcholine Receptor. ACS Medicinal Chemistry Letters, 2013, 4, 902-903.	2.8	0
21	Aminoquinoline Derivatives as HCV Inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 225-225.	2.8	0
22	Inhibitors of NS5A for Treatment of HCV Infection. ACS Medicinal Chemistry Letters, 2014, 5, 224-224.	2.8	0
23	Triazolo Derivatives as Inhibitors of PDE10A. ACS Medicinal Chemistry Letters, 2014, 5, 1069-1069.	2.8	0
24	Triazine Analogues as NS5B Inhibitors for the Treatment of HCV. ACS Medicinal Chemistry Letters, 2014, 5, 238-239.	2.8	0
25	Substituted Imidazothiazoles as Inhibitors of Viral Polymerase. ACS Medicinal Chemistry Letters, 2014, 5, 221-222.	2.8	0
26	Substituted Benzofurans as Inhibitors of HCV NS5B Protein. ACS Medicinal Chemistry Letters, 2014, 5, 223-223.	2.8	0
27	Imidazoquinolines as Novel Inhibitors of LRRK2 Kinase Activity. ACS Medicinal Chemistry Letters, 2019, 10, 148-149.	2.8	0
28	Novel Bis-heteroaryl Derivatives To Modulate Protein Aggregation for the Treatment of Neurodegenerative Diseases. ACS Medicinal Chemistry Letters, 2019, 10, 150-150.	2.8	0
29	Novel Pyrazolyl-dihydroisoquinolines as Positive Allosteric Modulator of the Dopamine D1 Receptor. ACS Medicinal Chemistry Letters, 2020, 11, 4-4.	2.8	0
30	Spiro-naphthyridine Antagonists of the Melanocortin Receptor 4 for the Treatment of Cachexia Associated with Chronic Illness. ACS Medicinal Chemistry Letters, 2022, 13, 997-998.	2.8	0